B
BIOA

Bailard’s BioAge Labs BIOA Stock Holding History

Bailard’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,700
Closed -$96.6K – 861
2025
Q1 		$96.6K Buy
+25,700
New +$119K ﹤0.01% 719

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Bailard's BIOA Position: Q2 2025 in Review

Bailard sold out of BioAge Labs (BIOA) in Q2 2025, closing a stake of 25,700 shares — an estimated $96.6K sold.

Bailard first reported a position in BIOA in Q1 2025 and held it in 1 quarter. The position peaked at $96.6K in Q1 2025. 83 funds tracked by Wall St. Rank hold BIOA as of Q2 2025.

  • Bailard reported no remaining BioAge Labs position as of Q2 2025 after selling out during the quarter.
  • Bailard sold 25,700 BioAge Labs shares in Q2 2025, an estimated $96.6K.
  • Bailard first reported a position in BioAge Labs in Q1 2025 and held it in 1 quarter.
  • Bailard's BioAge Labs position peaked at $96.6K in Q1 2025.
  • 83 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2025.

Based on Bailard's 13F filing for Q2 2025, filed 8 Aug 2025.